Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 18, 2017 04:22 ET | Source: NeuroDerm Ltd.

Mitsubishi Tanabe Pharma Corporation Completes Acquisition of NeuroDerm

REHOVOT, Israel, Oct. 18, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS)...
September 12, 2017 08:36 ET | Source: NeuroDerm Ltd.

NeuroDerm Shareholders Approve Proposed Acquisition by Mitsubishi Tanabe Pharma Corporation

REHOVOT, Israel, Sept. 12, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS)...
August 03, 2017 16:05 ET | Source: NeuroDerm Ltd.

NeuroDerm Announces Second Quarter 2017 Financial Results

REHOVOT, Israel, Aug. 03, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (NASDAQ:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS)...
August 01, 2017 16:05 ET | Source: NeuroDerm Ltd.

NeuroDerm Announces Extraordinary General Meeting of Shareholders to Approve Acquisition by Mitsubishi Tanabe Pharma Corporation

REHOVOT, Israel, Aug. 01, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS)...
July 24, 2017 02:00 ET | Source: NeuroDerm Ltd.

NeuroDerm Enters Definitive Agreement to be Acquired by Mitsubishi Tanabe Pharma Corporation for US$1.1 Billion in Cash

REHOVOT, Israel, July 24, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS)...
June 27, 2017 07:00 ET | Source: NeuroDerm Ltd.

Results of NeuroDerm’s ND0612H Phase II Trial Presented in Oral Session at the 3rd Congress of the European Academy of Neurology

-Complete reduction of OFF-time to zero in 42% of patients treated for 24 hours; statistically significant and clinically meaningful reduction in OFF-time and increase in the portion of patients ON by...
June 08, 2017 12:01 ET | Source: NeuroDerm Ltd.

NeuroDerm Presents Six Posters at the 21st International Congress of Parkinson’s Disease and Movement Disorders

REHOVOT, Israel, June 08, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS)...
June 06, 2017 09:05 ET | Source: NeuroDerm Ltd.

European Medicines Agency Accepts Design of NeuroDerm’s ND0612 Phase III iNDiGO Efficacy Trial

REHOVOT, Israel, June 06, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS)...
June 05, 2017 12:01 ET | Source: NeuroDerm Ltd.

NeuroDerm Presents ND0612H Phase II Trial Results in Late-Breaking Poster Session at the 21st International Congress of Parkinson’s Disease and Movement Disorders

-ND0612H achieved a complete reduction of OFF-time to zero in 42% of patients treated for 24 hours - - Statistically significant and clinically meaningful reduction in OFF-time and increase in the...
May 30, 2017 07:00 ET | Source: NeuroDerm Ltd.

NeuroDerm CEO to Present at the Jefferies Global Healthcare Conference on June 7, 2017

REHOVOT, Israel, May 30, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS)...